0.3991
전일 마감가:
$0.4052
열려 있는:
$0.42
하루 거래량:
1.52M
Relative Volume:
0.98
시가총액:
$19.16M
수익:
-
순이익/손실:
$-37.65M
주가수익비율:
-0.239
EPS:
-1.67
순현금흐름:
$-24.14M
1주 성능:
+2.02%
1개월 성능:
-40.79%
6개월 성능:
-77.45%
1년 성능:
-63.05%
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
RVPH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.3991 | 26.60M | 0 | -37.65M | -24.14M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-09-20 | 개시 | ROTH MKM | Buy |
2023-06-08 | 개시 | The Benchmark Company | Speculative Buy |
2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Is Reviva Pharmaceuticals Holdings Inc. a good long term investmentRapid profit acceleration - Autocar Professional
What drives Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock priceOutstanding risk-reward balance - Autocar Professional
What analysts say about Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock - Autocar Professional
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant a good long term investmentMassive stock growth - jammulinksnews.com
What analysts say about Reviva Pharmaceuticals Holdings Inc. stockRapid market gains - jammulinksnews.com
Reviva Pharmaceuticals Holdings Inc. Stock Analysis and ForecastStrongest growth potential - Autocar Professional
What drives Reviva Pharmaceuticals Holdings Inc. stock priceUnmatched profit potential - jammulinksnews.com
Can Reviva Pharmaceuticals Holdings Inc. stock recover from recent declineControlled Risk High Reward Plan - Newser
Reviva Pharmaceuticals Holdings Inc. Equity Warrant Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock performs during market volatilityWealth Building Stock Portfolio - Newser
Why Reviva Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock price move sharplyFree Stock Market Entry & Exit Signals - Newser
What makes Reviva Pharmaceuticals Holdings Inc. stock price move sharplyCapital Doubling Tips - Newser
Reviva Pharmaceuticals Holdings Inc: Analyzing RVPH Stock Trends - investchronicle.com
Why Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
How Reviva Pharmaceuticals Holdings Inc. stock performs during market volatilityReal Time Stock Signal - Newser
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals’ (RVPH) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Reviva Pharmaceuticals Makes A $10 Million Stock Offering Move - Finimize
Reviva Pharmaceuticals (RVPH) Maintains Buy Rating and Price Tar - GuruFocus
Reviva Pharmaceuticals (RVPH) Launches $10M Public Offering - GuruFocus
Dow Surges 200 Points; US GDP Contracts 0.5% - Benzinga
Reviva Pharmaceuticals (RVPH) Announces Public Offering of Commo - GuruFocus
Reviva Pharmaceuticals (RVPH) Declines After Announcing Public Offering - GuruFocus
Reviva Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan
Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):